2014, Food and Drug Administration, Patients and Side effects

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2014

Food and Drug Administration

Patients

Side effects

Biogen and Eisai’s Alzheimer’s drug secures support in closely watched AdCom

Pharmaceutical Technology

JUNE 12, 2023

A US Food and Drug Administration (FDA) Advisory Committee (AdCom) has unanimously voted in support of Eisai and Biogen’s Leqembi and its clinical benefit in patients with early Alzheimer’s disease , raising the drug’s full approval prospects. Notably, an FDA AdCom voted largely against Aduhelm in November 2020.

Food and Drug Administration

Food and Drug Administration Side effects Prospecting FDA

Novel oral chemotherapeutic holds potential for stomach cancer patients

European Pharmaceutical Review

JULY 5, 2022

Several lifestyle factors have been shown to increase the risk of developing stomach cancer, including alcohol consumption, smoking and consuming foods preserved by salts. There is an urgent need for more effective chemotherapy treatments with less severe toxicity and side effects.

Patients

Patients Food and Drug Administration Side effects Safety

Pharma Rep Focus

Biogen and Eisai’s Alzheimer’s drug secures support in closely watched AdCom

Novel oral chemotherapeutic holds potential for stomach cancer patients

Stay Connected